Recombinant virus immunotherapy

Details Recombinant virus immunotherapy Recombinant virus immunotherapy

C - Chemistry, Metallurgy

12

N

C12N 7/01 (2006.01) A61K 39/00 (2006.01) A61K 39/12 (2006.01) A61K 39/145 (2006.01) A61K 39/205 (2006.01) C07K 14/47 (2006.01) C07K 14/52 (2006.01) C07K 14/525 (2006.01) C07K 14/535 (2006.01) C07K 14/54 (2006.01) C07K 14/55 (2006.01) C07K 14/57 (2006.01) C07K 14/705 (2006.01) C07K 14/82 (2006.01) C12N 7/00 (2006.01) C12N 15/12 (2006.01) C12N 15/19 (2006.01) C12N 15/86 (2006.01) C12N 15/863 (2006.01)

Patent

CA 2153336

Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor, nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN-.gamma.; IL.-4; GMCSF; IL-12; B7; erb-B- 2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

Affiliated with

Also associated with

Rating

Recombinant virus immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant virus immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant virus immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2076221